Purdue Pharma To Dissolve As Judge-Approved Opioid Settlement Takes Effect
Purdue Pharma will dissolve after a judge on Tuesday, April 28, 2026 approved a criminal sentence tied to the company's opioid settlement, putting the court-backed breakup into effect.
The judge's order activates terms of a long-running agreement meant to resolve criminal and civil claims over OxyContin and to fund payments to states, cities and victims, a move that begins the legal process to wind down the company.
The episode traces back to lawsuits alleging the company misled doctors about the risks and addictive properties of OxyContin, sparking state and local suits across the country and years of litigation before the court-approved deal.
Officials and litigation leaders will now work to implement the judge's order and dissolve corporate structures, a process that could take months and draw appeals.
Show source details & analysis (1 source)
📌 Key Facts
- Purdue Pharma will be dissolved and replaced by a public-benefit style company by the end of the week of April 27–May 1, 2026.
- A federal bankruptcy judge approved the broader criminal sentence and settlement in November, including $8.3 billion in penalties but only $225 million to be collected by the federal government.
- The Sackler family is to pay up to $7 billion over 15 years, contributing to settlements exceeding $50 billion, with individual victim payments expected to range from about $8,000 to $16,000.
- On Tuesday, April 28, 2026, 31 people affected by opioid addiction addressed the court, with many asking the judge to reject the plea deal and calling for further prosecution.
📰 Source Timeline (1)
Follow how coverage of this story developed over time